TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 seropositive~2. Age \> 21 years~3. Receiving ATP \> 2 years as their only ART, with HIV-1 RNA \< 50 copies/mL at screening and all HIV-1 RNA tests \< 100 copies/mL in the past 18 months~4. No documented resistance mutations to the components of ATP~5. Any CD4 count, but no active AIDS-defining opportunistic infections or cancers~6. HBsAg+ permitted if plasma HBV DNA is unquantifiable and the patient does not have decompensated liver disease~Exclusion Criteria:~1. Pregnancy, breastfeeding or planned pregnancy in the next 2 years~2. Documented resistance to the components of ATP~3. Active AIDS-defining opportunistic infection or cancer~4. Cancer in past 3 years, except non melanoma skin cancer~5. Active psychotic disease or active depression that may interfere with study participation according investigator discretion~6. Any illness with a life expectancy less than 2 years~7. eGFR \< 50 mL/min~8. Urine protein/creatinine \> 40 mg/mmoL~9. Patients who the investigator feels are unlikely to commit to the study requirements for any reason~10. Prescription drug therapy for osteoporosis (calcium and/or vitamin D is allowed)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B/F/TAF (Type: EXPERIMENTAL): B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks
- Atripla (Type: ACTIVE_COMPARATOR): Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a. adult (≥ 18 year) patients; b. signed informed consent before surgical procedure; c. severe sepsis or septic shock; d. at least one of the following conditions: i) post-operative peritonitis, ii) recurrent gastrointestinal perforation, iii) post-operative hepatobiliary and/or pancreatic disorders including necrotizing pancreatitis, iv) post-operative intra-abdominal abscess, and v) anastomotic leak.~Exclusion Criteria:~* a. diagnosis of candidiasis before the enrollment b. exposure in the past 30 days to any antifungal treatment or diagnosis of invasive fungal infection; c. pregnancy or lactation; d. history of allergy to any of the antifungal drugs; e. major immunosuppression conditions including: i. neutropenia (\<0.5 × 109 neutrophils/L \[\<500 neutrophils/mm3\] for \>10 days), ii. receipt of an allogeneic stem cell transplant or solid organ transplantation, iii. inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency), iv. HIV infection with lymphocyte T CD4+ cell count \< 200/mmc. f. patients with poor prognosis or unable to sign informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- De-escalation (Type: EXPERIMENTAL): In this group, investigators will manage the antifungal therapy according to the BG levels as follows:~1. antifungal therapy will be stopped immediately after the BG response in case of serum BG \<80 pg/ml in presence of clinical stability (CS);~2. antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG \<80 pg/ml in patients without CS. In these cases, if the following BG value is \<80 pg/ml antifungal therapy will be stopped independently from the CS achievement.~3. antifungal therapy will be continued until day 10 for BG levels \>200 pg/ml
- Standard of care (Type: NO_INTERVENTION): In this group antifungal treatment will be continued until clinician's decision.~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with pathologically confirmed breast cancer with any receptor status, who will receive neoadjuvant chemotherapy. Patients with denovo oligo-metastatic disease, where the intent of therapy is curative with incorporation of local therapy (surgery/radiation to the breast and/or metastatic sites) are also eligible.~* Age \>= 18 years~* Ability to understand and the willingness to sign a written informed consent~* Willingness to wear sensors to track physical activity, global positioning system (GPS) location, and provide symptom ratings each night during the screening period of their clinical trial and 180 days after starting treatments~* Able to read English, Spanish, or Mandarin to complete patient reported outcomes~* Able to ambulate without an assistive device~Exclusion Criteria:~* Missing lower limbs~* Known movement disorder such as Parkinson's disease, choreo-athetoid movement disorders, essential tremor if that movement disorder is of sufficient severity to require drug therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational (movement assessment, medical data collection) (Type: None): Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.~* Willingness to refrain from a change in diet/drinking/exercise/medication regimen for the entire course of the study.~* For female of child bearing potential - using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, Intra Uterine Device (IUD), contraceptive implant, barrier methods with spermicide, or abstinence).~Exclusion Criteria:~* Pregnant or planning to become pregnant, having given birth less than 9 months ago, and/or breastfeeding.~* Having any active electrical implant anywhere in the body,~* Having a permanent implant in the treated areas~* Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.~* Having undergone a liposuction surgery or any contouring treatment in the areas intended for treatment within 2 years of treatment~* Having or undergoing any form of cancer~* Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.~* Having a anticoagulative or thromboembolic condition or taking anticoagulation medications~* History of immunosuppression/immune deficiency disorders~* Suffering from hormonal imbalance which may affect weight or cellulite~* History of significant lymphatic drainage problems.~* History of keloid scarring or of abnormal wound healing.~* History of being especially prone to bruising.~* History of epidermal or dermal disorders~* Use of isotretinoin within 6 months~* Significant change in diet or exercise regimen within a month of enrollment or during this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of enrollment or during this study.~* Participation in a study of another device or drug within 1 month prior to enrollment or during this study.~* As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
- Control Group (Type: SHAM_COMPARATOR): Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Frozen embryo transfer patients, men over the age of 18 and women between the ages of 18 and 42 completed years (if using their own eggs and with embryos frozen before 39 completed years) or 18 to 50 completed years if using donated eggs.~Exclusion Criteria:~* Prior participation in this study, blastocyst transfers, single embryo transfer for medical reasons, prior embryo transfer with large amount of blood on the outside of the catheter, \> or = 3 consecutive failed embryo transfers at Mayo Clinic (fresh or frozen-thawed cycles).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Factors of Obesity-hypoventilation Syndrome (OHS) Among Obese Subjects- ETUDE COHYPOB -

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Obese volunteer Subject (BMI\> 30 kg/m2)~* Adults of either sex~* Social security affiliation~* Written informed consent~Exclusion criteria:~* Confirmed OHS at baseline defined by a daytime hypercapnia with PaCO2\> 45mmHg~* Any cause of chronic respiratory failure other than obesity such as COPD, chest deformation, phrenic nerve paralysis, pulmonary fibrosis, neuromuscular disease, a history of mutilating thoracic surgery ...~* Obstructive ventilatory defect with FEV1/ FVC \<70% post-bronchodilator~* Long term oxygen therapy, noninvasive ventilation, continuous positive airway pressure~* Any serious illness involving life-threatening within 3 years after inclusion~* Drug or alcohol abuse~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Obesity: BMI > 30 kg/m2 (Type: OTHER): Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Registry of Immediate/Delayed Loading of Implants in the Cranial Bone-grafted Severely Atrophic Jaw

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of all ages~* Patients of all genders~* Patients with moderate to extreme bone atrophy of the jaw (class IV to VI according to Cawood and Howell (Cawood \& Howell, 1988), caused by terminal periodontitis or edentulism~* Patients requiring bone augmentation procedures through cranial bone grafting for jaw reconstruction~* Patients ineligible for conventional removable prosthetic rehabilitation~Exclusion Criteria:~* Patients not eligible according to abovementioned criteria~* Patients with severe uncontrolled diabetes~* Patients with cranial vault without diploe and/or cranial vault thickness \<3mm, as defined with cone-beam CT (De Ceulaer, et al., 2012)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tezosentan in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Male and female patients 18 years of age or older~3. Patients with PAH according to one of the following subgroups of the Venice Classification Group 1:~   * Idiopathic (iPAH), or~  * Familial/heritable (FPAH), or~  * Associated (APAH) with collagen vascular disease~4. Modified NYHA functional class II-III~5. Documented hemodynamic diagnosis of PAH by right heart catheterization at Baseline:~   * Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and~  * Resting mean PVR ≥ 240 dyn•s•cm-5 and~  * Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg~Exclusion Criteria:~1. Patients with PAH in Venice Classification Groups 2-5, and PAH Group 1 subgroups not covered by inclusion criterion no. 3~2. Hypotensive patients (systemic systolic blood pressure \< 100 mmHg)~3. Patients with body weight \< 50 kg (110 lbs)~4. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)~5. Patients with clinically significant chronic renal insufficiency (serum creatinine \> 2.5mg/dL / 221µmol/L)~6. Patients who have received any endothelin receptor antagonist (ERA) and/or any phosphodiesterase-5 (PDE-5) inhibitor within 28 days of Baseline~7. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g., treprostinil, iloprost) within 28 days of Baseline~8. Patients who have received any investigational drugs within 28 days of Baseline~9. Patients who have received cyclosporine A or tacrolimus within 28 days of Baseline~10. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with the study~11. Life expectancy less than 12 months~12. Females who are lactating or pregnant or females who are not using a reliable method of birth control (failure rate less than 1% per year) during the study and for at least one month after study drug intake~13. Known hypersensitivity to any of the excipients of the drug formulation~14. Patients with positive response to vasoreactivity test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tezosentan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject voluntarily gives informed consent to participate in the study.~2. The subject participated in study RIN-PH-201, remained on study drug, was compliant with RIN-PH-201 study procedures or was enrolled in study RIN-PH-201 at the time that the study was discontinued by the sponsor.~3. Females of reproductive potential must be non-pregnant (as confirmed by a urine pregnancy test at Baseline) and non-lactating, and will:~   * Either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or~  * Use two medically acceptable, highly-effective forms of contraception for the duration of study, and at least 30 days after discontinuing study drug.~4. Males must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.~Exclusion Criteria:~1. The subject is pregnant or lactating.~2. The subject was prematurely discontinued from study RIN-PH-201.~3. The subject developed a concurrent illness or condition during the conduct of RIN-PH-201 which, in the opinion of the Investigator, would represent a risk to overall health if they enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled Treprostinil (Type: EXPERIMENTAL): Open-label access

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject was diagnosed with chronic plaque psoriasis at least 6 months before randomisation.~* Subject has a diagnosis of moderate-to-severe plaque psoriasis as defined by PASI ≥12, sPGA ≥3, and body surface area ≥10% at screening and at baseline.~* Subject, in whom topical therapy is not adequate, and who is a candidate for systemic therapy.~* Subject has no evidence of active or latent tuberculosis according to local standard of care.~Key Exclusion Criteria:~* Subject is diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions (e.g., eczema).~* Subject has been vaccinated with a tetanus toxoid-containing vaccine ≤18 months prior to first dose of investigational medicinal product (IMP). For EU and UK: Subject has been vaccinated with a TT-containing vaccine within 5 years prior to the first dose of IMP.~* Subject has developed or experienced either Guillian-Barre syndrome, encephalopathy, Arthus-type hypersensitivity, or severe allergic reactions in connection with previous Tdap or Td vaccine.~* Subject with chronic or recurrent infections, or active infection, systemically treated within 4 weeks prior to first dose of IMP.~* Subject has a known history of Crohn's disease.~* Subject has any active malignancy or a history of any malignancy within 5 years.~* Subject has a history of suicidal behaviour and has suicidal ideation with some intent to act or specific plan and intent.~* Subject has a history of depressive disorder with severe episode(s) within the last 2 years.~* Subject has received anti-IL-12/23p40 for less than 12 months prior to the first dose of IMP or has previously no response to anti-IL-12/23p40 therapy.~* Subject has previously received anti-IL-17 therapy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Brodalumab (Type: EXPERIMENTAL): Brodalumab for 52 weeks. The dose will be determined by the participant's body weight.
- Ustekinumab (Type: ACTIVE_COMPARATOR): Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
- Placebo/brodalumab (Type: PLACEBO_COMPARATOR): Placebo for the first 12 weeks and brodalumab for the following 40 weeks. The dose will be determined by the participant's body weight.
- Placebo/ustekinumab (Type: PLACEBO_COMPARATOR): Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gene Expression in MS Patients Before and During Treatment With Interferon-beta

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of relapsing-remitting MS (McDonald criteria)~* age between 18-55~* EDSS less or equal to 5.5~Exclusion Criteria:~* use of any other disease modifying drugs~* use of corticosteroids during 3 months before starting protocol~* clinical relapse during 1 month before starting protocol~* serious heart, renal, hepatic or haematological dysfunction defined by laboratory exams

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues